191 related articles for article (PubMed ID: 21773753)
1. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry.
Falzarano SM; Zhou M; Carver P; Tsuzuki T; Simmerman K; He H; Magi-Galluzzi C
Virchows Arch; 2011 Oct; 459(4):441-7. PubMed ID: 21773753
[TBL] [Abstract][Full Text] [Related]
2. Antibody-based detection of ERG rearrangement-positive prostate cancer.
Park K; Tomlins SA; Mudaliar KM; Chiu YL; Esgueva R; Mehra R; Suleman K; Varambally S; Brenner JC; MacDonald T; Srivastava A; Tewari AK; Sathyanarayana U; Nagy D; Pestano G; Kunju LP; Demichelis F; Chinnaiyan AM; Rubin MA
Neoplasia; 2010 Jul; 12(7):590-8. PubMed ID: 20651988
[TBL] [Abstract][Full Text] [Related]
3. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
[TBL] [Abstract][Full Text] [Related]
4. TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.
Gopalan A; Leversha MA; Dudas ME; Maschino AC; Chang J; Al-Ahmadie HA; Chen YB; Tickoo SK; Reuter VE; Fine SW
Histopathology; 2013 Aug; 63(2):279-86. PubMed ID: 23701505
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.
Esgueva R; Perner S; J LaFargue C; Scheble V; Stephan C; Lein M; Fritzsche FR; Dietel M; Kristiansen G; Rubin MA
Mod Pathol; 2010 Apr; 23(4):539-46. PubMed ID: 20118910
[TBL] [Abstract][Full Text] [Related]
6. ERG rearrangement is present in a subset of transition zone prostatic tumors.
Falzarano SM; Navas M; Simmerman K; Klein EA; Rubin MA; Zhou M; Magi-Galluzzi C
Mod Pathol; 2010 Nov; 23(11):1499-506. PubMed ID: 20693982
[TBL] [Abstract][Full Text] [Related]
7. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
Chaux A; Albadine R; Toubaji A; Hicks J; Meeker A; Platz EA; De Marzo AM; Netto GJ
Am J Surg Pathol; 2011 Jul; 35(7):1014-20. PubMed ID: 21677539
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort.
Svensson MA; Perner S; Ohlson AL; Day JR; Groskopf J; Kirsten R; Sollie T; Helenius G; Andersson SO; Demichelis F; Andrén O; Rubin MA
Appl Immunohistochem Mol Morphol; 2014; 22(2):136-41. PubMed ID: 24517914
[TBL] [Abstract][Full Text] [Related]
10. ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis.
Gao X; Li LY; Zhou FJ; Xie KJ; Shao CK; Su ZL; Sun QP; Chen MK; Pang J; Zhou XF; Qiu JG; Wen XQ; Yang M; Bai XZ; Zhang H; Ling L; Chen Z
Clin Cancer Res; 2012 Aug; 18(15):4163-72. PubMed ID: 22696228
[TBL] [Abstract][Full Text] [Related]
11. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
Berg KD; Brasso K; Thomsen FB; Røder MA; Holten-Rossing H; Toft BG; Iversen P; Vainer B
J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
[TBL] [Abstract][Full Text] [Related]
12. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.
Tomlins SA; Palanisamy N; Siddiqui J; Chinnaiyan AM; Kunju LP
Arch Pathol Lab Med; 2012 Aug; 136(8):935-46. PubMed ID: 22849743
[TBL] [Abstract][Full Text] [Related]
13. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
[TBL] [Abstract][Full Text] [Related]
14. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
Scheble VJ; Braun M; Beroukhim R; Mermel CH; Ruiz C; Wilbertz T; Stiedl AC; Petersen K; Reischl M; Kuefer R; Schilling D; Fend F; Kristiansen G; Meyerson M; Rubin MA; Bubendorf L; Perner S
Mod Pathol; 2010 Aug; 23(8):1061-7. PubMed ID: 20473283
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement.
de Muga S; Hernández S; Salido M; Lorenzo M; Agell L; Juanpere N; Lorente JA; Serrano S; Lloreta J
Cancer Biomark; 2012-2013; 12(1):21-30. PubMed ID: 23321466
[TBL] [Abstract][Full Text] [Related]
18. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
[TBL] [Abstract][Full Text] [Related]
20. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
